- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial completion: Prochymal (clinicaltrials.gov) - Sep 21, 2016
P2, N=220, Completed,
Trial primary completion date: Jan 2017 --> Sep 2017 Active, not recruiting --> Completed
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial completion, Trial primary completion date: Safety and Treatment Outcome Study of PROCHYMAL (clinicaltrials.gov) - May 20, 2015
P=N/A, N=11, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial completion: PROCHYMAL (clinicaltrials.gov) - Dec 7, 2014
P2, N=63, Completed,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Active, not recruiting --> Completed
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Enrollment closed: Evaluation of PROCHYMAL (clinicaltrials.gov) - Jun 27, 2014
P3, N=120, Active, not recruiting,
Active, not recruiting --> Withdrawn Recruiting --> Active, not recruiting
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Enrollment closed: Evaluation of PROCHYMAL (clinicaltrials.gov) - Jun 27, 2014
P3, N=330, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial primary completion date: Evaluation of PROCHYMAL (clinicaltrials.gov) - May 18, 2014
P3, N=120, Recruiting,
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2014 --> Jul 2017
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial primary completion date: Evaluation of PROCHYMAL (clinicaltrials.gov) - May 18, 2014
P3, N=330, Recruiting,
Trial primary completion date: Jan 2014 --> Jul 2017 Trial primary completion date: Jan 2014 --> Dec 2016
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial completion date: Evaluation of PROCHYMAL (clinicaltrials.gov) - May 18, 2014
P3, N=120, Recruiting,
Trial primary completion date: Jan 2014 --> Dec 2016 Trial completion date: Jun 2014 --> Jul 2017
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial completion date: Evaluation of PROCHYMAL (clinicaltrials.gov) - May 18, 2014
P3, N=330, Recruiting,
Trial completion date: Jun 2014 --> Jul 2017 Trial completion date: Dec 2015 --> Dec 2018
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Enrollment change: Evaluation of PROCHYMAL (clinicaltrials.gov) - May 18, 2014
P3, N=330, Recruiting,
Trial completion date: Dec 2015 --> Dec 2018 N=270 --> 330
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Enrollment closed: Safety and Treatment Outcome Study of PROCHYMAL (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=10, Active, not recruiting,
N=270 --> 330 Enrolling by invitation --> Active, not recruiting
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Enrollment change: Safety and Efficacy of Prochymal (clinicaltrials.gov) - Oct 9, 2012
P2, N=15, Completed,
Active, not recruiting --> Completed N=30 --> 15
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial completion, Combination therapy: Efficacy and Safety of Prochymal (clinicaltrials.gov) - Apr 30, 2012
P3, N=184, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Enrollment change: Extended Evaluation of PROCHYMAL (clinicaltrials.gov) - Oct 6, 2011
P3, N=98, Completed,
Active, not recruiting --> Completed N=200 --> 98
- |||||||||| Ryoncil (remestemcel-L) / Mallinckrodt, JCR Pharma
Trial completion: PROCHYMAL (clinicaltrials.gov) - Sep 25, 2011
P2, N=62, Completed,
N=200 --> 98 Active, not recruiting --> Completed
|
